دورية أكاديمية
COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease.
| العنوان: | COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease. |
|---|---|
| المؤلفون: | Chan KW; Department of Medicine, The University of Hong Kong, Hong Kong., Wong VT; School of Chinese Medicine, The University of Hong Kong, Hong Kong., Tang SCW; Department of Medicine, The University of Hong Kong, Hong Kong. |
| المصدر: | The American journal of Chinese medicine [Am J Chin Med] 2020; Vol. 48 (3), pp. 737-762. Date of Electronic Publication: 2020 Mar 13. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: World Scientific Pub Country of Publication: Singapore NLM ID: 7901431 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1793-6853 (Electronic) Linking ISSN: 0192415X NLM ISO Abbreviation: Am J Chin Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003->: Singapore ; River Edge, NJ : World Scientific Pub. Original Publication: [Garden City, N.Y.] : Institute for Advanced Research in Asian Science and Medicine |
| مواضيع طبية MeSH: | Integrative Medicine* , Medicine, Chinese Traditional*, Coronavirus Infections/*therapy , Pneumonia, Viral/*therapy, Betacoronavirus ; COVID-19 ; Clinical Trials as Topic ; Coronavirus Infections/pathology ; Humans ; Pandemics ; Pneumonia, Viral/pathology ; Practice Guidelines as Topic ; SARS-CoV-2 |
| مستخلص: | As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese medicine could be considered as an adjunctive therapeutic option in the management of COVID-19. |
| فهرسة مساهمة: | Keywords: 2019-nCoV; COVID-19; Chinese Medicine; Guideline; Integrative Medicine; Review |
| تواريخ الأحداث: | Date Created: 20200314 Date Completed: 20200512 Latest Revision: 20201218 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1142/S0192415X20500378 |
| PMID: | 32164424 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1793-6853 |
|---|---|
| DOI: | 10.1142/S0192415X20500378 |